Last updated: August 12, 2026
ShopRite Dual Action Complete is a private-label OTC chewable acid reducer built around famotidine, calcium carbonate, and magnesium hydroxide. Its commercial value comes from rapid symptom relief, recognizable dual-action positioning, low manufacturing complexity, and retailer control over pricing and shelf placement. The main product-development opportunities are improved taste, tablet texture, sugar-free delivery, packaging efficiency, and line extensions rather than new therapeutic claims.
What is the active-ingredient composition of ShopRite Dual Action Complete?
ShopRite Dual Action Complete is positioned as a Pepcid Complete-type combination product:
| Component |
Typical strength per chewable tablet |
Function |
| Famotidine |
10 mg |
H2-receptor antagonist that reduces gastric acid secretion |
| Calcium carbonate |
800 mg |
Rapid acid neutralization |
| Magnesium hydroxide |
165 mg |
Antacid with complementary neutralizing activity |
The combination uses two mechanisms. Calcium carbonate and magnesium hydroxide provide rapid relief, while famotidine suppresses additional acid production. The formulation is intended for heartburn and acid indigestion rather than chronic disease management.
The product is a small-molecule OTC drug. It is not a biologic and has no biosimilar pathway. Its regulatory and commercial competition comes from private-label antacids, generic famotidine products, branded combination products, and single-ingredient calcium carbonate or famotidine products.
What excipients are most important in a dual-action chewable tablet?
The excipient system must solve four technical problems: high active loading, acceptable mouthfeel, rapid dissolution, and suppression of the metallic or chalky taste associated with mineral antacids.
A representative excipient architecture for this product category includes:
| Excipient function |
Candidate excipients |
Commercial and technical purpose |
| Diluent and compression aid |
Microcrystalline cellulose, mannitol, sorbitol |
Supports tablet weight, hardness, and mouthfeel |
| Sweetener |
Sucralose, aspartame, acesulfame potassium, saccharin sodium |
Masks mineral bitterness and famotidine taste |
| Bulking sweetener |
Sorbitol, mannitol, maltitol |
Improves chewability and consumer acceptability |
| Superdisintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Promotes breakup after chewing and swallowing |
| Binder |
Povidone or co-processed cellulose systems |
Controls tablet robustness during manufacture |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow and weight uniformity |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces sticking and ejection force |
| Flavor |
Mint, peppermint, fruit-mint, or berry systems |
Covers mineral and H2-antagonist taste |
| Anti-adherent |
Talc or selected silica systems |
Reduces tooling adhesion |
| Coating or polishing aid |
Carnauba wax or film-coating system |
Improves appearance and handling |
The final excipient list must be confirmed against the product’s specific NDC label because private-label manufacturers can change inactive ingredients without changing the active-ingredient declaration. Product-specific labeling is available through DailyMed and FDA OTC labeling records.[1,2]
How should the excipient strategy address calcium carbonate and magnesium hydroxide?
The mineral actives create the largest formulation burden. Calcium carbonate has a chalky texture, high density, alkaline reactivity, and potential for tablet sticking. Magnesium hydroxide can contribute to grittiness and an unpleasant aftertaste.
Particle-size control
Fine, narrow particle-size distributions improve mouthfeel but can reduce powder flow and increase dusting. Coarser particles improve flow but create a gritty chew. A controlled bimodal distribution can balance compressibility with oral texture.
The preferred approach is to qualify pharmaceutical-grade mineral powders with:
- Controlled median particle size
- Low heavy-metal content
- Low moisture
- Consistent neutralizing capacity
- Low microbiological burden
- Stable bulk density
Particle-size specifications are a meaningful supplier-control opportunity because mineral variability can affect tablet weight, hardness, dissolution, and consumer perception.
Taste masking
Taste masking should combine flavor and sweetener rather than rely on a single high-intensity sweetener. Mineral alkalinity can remain noticeable after the initial flavor pulse. A layered approach is more effective:
- Immediate sweetness from a high-intensity sweetener.
- Bulk and cooling sensation from mannitol or sorbitol.
- Mint or fruit-mint flavor for mineral suppression.
- Optional polymeric or lipid-based coating of famotidine particles.
Famotidine is present at a much lower mass than the mineral actives, but its bitterness can remain perceptible because the tablet dissolves in the mouth. Coating or granulating famotidine separately can permit lower flavor loading and better batch consistency.
Chewability
A commercial chewable should break under moderate chewing force without becoming friable during shipping. Excessive hardness slows disintegration and leaves a chalky residue. Excessive softness causes capping, chipping, and packaging losses.
Mannitol is attractive for premium formulations because it produces a clean, cooling mouthfeel. Sorbitol is usually more economical but is hygroscopic and can create stability or tackiness problems. A mixed polyol system can reduce cost while maintaining acceptable chewability.
What formulation patents could protect a future ShopRite product?
The active ingredients themselves have limited protection value. A future patent strategy would need to focus on formulation or manufacturing performance.
Potential claim areas include:
Taste-masked famotidine particles
A patent could cover coated famotidine particles dispersed in a mineral antacid matrix. Relevant claim elements might include:
- Coating polymer or lipid composition
- Coating weight gain
- Particle-size range
- Dissolution profile
- Reduced bitterness score
- Stability under accelerated storage
The commercial value is strongest if the coating improves taste without delaying famotidine release beyond the expected OTC performance profile.
Low-grit mineral matrix
A formulation patent could target a defined calcium carbonate and magnesium hydroxide particle-size combination with a specified tablet hardness and oral texture. The strongest claims would connect physical parameters to a measurable consumer benefit.
Sugar-free or reduced-sugar chewable
A sugar-free product could use mannitol, sorbitol, erythritol, maltitol, or combinations with high-intensity sweeteners. Patentability would depend on a non-obvious combination and demonstrated performance, not on simply replacing sucrose.
The main technical risk is gastrointestinal tolerance. Polyols can cause bloating or laxation at higher exposure. A formulation that minimizes total polyol content while maintaining taste could support differentiated claims and a stronger patent position.
Rapid-onset combination product
A manufacturer could seek protection for separate granulation or particle populations that release antacid components rapidly while delivering famotidine consistently. A release-profile claim would need strong analytical support and a meaningful distinction from existing combination products.
Manufacturing process
Process claims could address:
- Separate granulation of famotidine and mineral components
- Low-moisture granulation
- Direct compression using a co-processed excipient
- Controlled lubrication to reduce dissolution delay
- Tablet dedusting and packaging controls
Process protection is more useful when the manufacturing method materially reduces defects or permits a lower-cost formula.
What is the FDA regulatory status and Orange Book position?
ShopRite Dual Action Complete is an OTC product, not a conventional prescription product. Its regulatory pathway is based on FDA OTC requirements, applicable monograph conditions, labeling rules, current good manufacturing practice, and product-specific quality controls.[2,3]
The product is not expected to have a conventional Orange Book patent listing because Orange Book listings primarily concern approved prescription and certain other FDA-approved products with patent and exclusivity information. An OTC store-brand product does not ordinarily create an Orange Book patent barrier equivalent to a branded prescription drug.[4]
Key regulatory considerations include:
- Compliance with the applicable OTC antacid and acid-reducer requirements
- Active-ingredient strength and permitted combinations
- Required warnings and directions
- Drug Facts labeling
- Stability and finished-product testing
- Manufacturing controls for mineral raw materials
- Child-resistant packaging where required
- Labeling controls for phenylalanine if aspartame is used
- Accurate allergen and inactive-ingredient declarations
The product does not require a Paragraph IV certification in the same manner as an abbreviated new drug application for a listed prescription drug. A competing manufacturer can generally enter through its own compliant OTC product pathway rather than challenge a listed Orange Book patent.
When does ShopRite Dual Action Complete lose exclusivity?
The product has no conventional prescription exclusivity period. Its commercial exclusivity is retailer-based rather than patent-based.
ShopRite can preserve practical differentiation through:
- Retailer-controlled branding
- Supplier agreements
- Packaging design
- Shelf placement
- Price promotion
- Multi-pack configurations
- Store distribution
- Consumer loyalty programs
A competing manufacturer can market a therapeutically equivalent OTC product if it satisfies FDA requirements. The main barriers are manufacturing qualification, retailer access, quality consistency, and consumer recognition.
No conventional biosimilar risk exists. Generic substitution is also less structured than in the prescription market because the product is sold directly to consumers and selected by brand, price, dosage form, and retailer availability.
What commercial opportunities exist for excipient suppliers?
The highest-value opportunity is not a single excipient. It is an integrated chewable-tablet platform that improves taste, texture, throughput, and stability.
Premium sugar-free formulation
A sugar-free version could target consumers managing sugar intake. The formulation should minimize total polyol loading and control cooling sensation. Mannitol-based systems may offer better mouthfeel, while sorbitol-based systems may provide lower cost and stronger binding.
Fast-dissolving tablet
A fast-dissolving chewable could support a rapid-relief consumer proposition. The formulation must avoid excessive compression force and excessive hydrophobic lubrication, both of which can delay wetting and disintegration.
Better flavor systems
Mint is established in antacid products, but fruit-mint and citrus-mint systems could create retailer differentiation. Flavor suppliers could commercialize encapsulated flavors that survive compression and release during chewing.
Pediatric-adjacent family positioning
A lower-strength or separate pediatric product could expand the category, but famotidine and antacid combinations require careful age-specific labeling and safety review. A family-oriented line should not assume that an adult combination formula can be extended directly to children.
Premium packaging
Blister packaging can improve dose portability and reduce moisture exposure. Bottles are generally lower cost for high-volume retail but may create greater exposure to humidity and tablet abrasion. Unit-dose sachets or small blister cards could support travel and convenience channels.
Retailer-exclusive line extensions
Potential line extensions include:
| Product concept |
Primary opportunity |
| Sugar-free chewable |
Health-conscious consumers |
| Mint-free or fruit-flavored chewable |
Consumers who dislike strong mint |
| Smaller tablet format |
Improved portability and swallowing comfort |
| Twin-pack or travel blister |
Convenience and higher basket value |
| Nighttime acid-control product |
Separate use case, subject to labeling review |
| Single-ingredient famotidine |
Lower-cost alternative |
| Calcium carbonate-only product |
Entry-price antacid segment |
A manufacturer should avoid excessive line proliferation. The strongest commercial candidates are sugar-free, improved-flavor, and travel-format versions because they use the same therapeutic category while creating visible shelf differentiation.
How strong is the patent estate for this product category?
The patent estate is weak at the active-ingredient level and potentially moderate at the formulation level.
| Protection category |
Strategic strength |
| Famotidine active ingredient |
Low; mature generic molecule |
| Calcium carbonate and magnesium hydroxide |
Very low; established antacid ingredients |
| Combination concept |
Low to moderate, depending on claim scope |
| Taste masking |
Moderate if supported by measurable performance |
| Sugar-free chewable |
Low to moderate |
| Release-control architecture |
Moderate if technically differentiated |
| Manufacturing process |
Moderate where cost or quality benefits are demonstrated |
| Brand and packaging |
Commercially important but not patent exclusivity |
A company seeking defensible protection should file before commercial launch and separate formulation claims from process claims. Trade secrets may be more valuable than patents for flavor ratios, mineral sourcing specifications, compression settings, and supplier qualification methods.
Which companies are likely to challenge the product commercially?
Competition is likely to come from:
- Haleon, through Pepcid Complete and related acid-reducer products
- Perrigo, through store-brand and private-label OTC manufacturing
- Kenvue and other large OTC portfolio companies
- CVS, Walgreens, Walmart, Target, and supermarket private-label programs
- Contract manufacturers supplying regional grocery chains
- Generic famotidine and antacid manufacturers
The competitive threat is primarily price and distribution based. Private-label products can achieve acceptable margins with mature ingredients, but retailer switching costs are low if another supplier can match specifications and reduce cost.
What generic launch risks exist for ShopRite Dual Action Complete?
The principal risks are operational rather than patent-driven:
- Mineral raw-material variability can cause tablet and taste failures.
- Inadequate taste masking can reduce repeat purchase.
- High polyol content can create tolerance complaints.
- Moisture sensitivity can cause softening, sticking, or reduced stability.
- Excessive tablet hardness can slow breakup.
- Poor packaging can increase chipping and odor transfer.
- A supplier change can alter flavor, texture, or dissolution without an obvious label change.
- Retailer price compression can reduce manufacturer margins.
The most defensible development package combines a robust excipient platform, a qualified dual-source mineral supply, in-process texture controls, and packaging that protects the chewable tablet from humidity and abrasion.
Key Takeaways
- ShopRite Dual Action Complete is a private-label OTC combination centered on famotidine, calcium carbonate, and magnesium hydroxide.
- Its main formulation challenge is masking mineral chalkiness and famotidine bitterness while preserving rapid breakup.
- Mannitol, sorbitol, microcrystalline cellulose, superdisintegrants, flavor systems, and controlled lubrication are the main excipient levers.
- Active-ingredient patent protection is not the commercial barrier; retailer access, manufacturing quality, and consumer preference determine market performance.
- The strongest opportunities are sugar-free, improved-flavor, fast-dissolving, and travel-pack formats.
- Formulation and process patents may provide moderate protection, but trade secrets and retailer agreements are likely to have greater practical value.
- The product has no biosimilar risk and generally does not present a conventional Orange Book or Paragraph IV barrier.
FAQs
Can ShopRite Dual Action Complete use a novel excipient?
A novel excipient would increase regulatory complexity and would rarely be necessary for this mature OTC combination. A formulation based on established excipients listed in FDA’s Inactive Ingredient Database is commercially preferable.[5]
Is magnesium hydroxide necessary in a famotidine chewable?
Magnesium hydroxide is not required for famotidine activity, but it contributes immediate acid-neutralizing capacity and supports the dual-action positioning. Removing it would create a different formulation and potentially require new performance and labeling substantiation.
Is mannitol better than sorbitol for this product?
Mannitol generally offers a cleaner, less hygroscopic mouthfeel. Sorbitol can reduce cost and improve binding but requires tighter moisture and gastrointestinal-tolerance controls. A blended system may offer the best commercial balance.
Can a private-label manufacturer patent a ShopRite chewable formulation?
Yes, if the formulation or manufacturing process contains a novel and non-obvious technical feature supported by data. A simple substitution of one sweetener or flavor for another would usually provide limited patent strength.
What is the most attractive commercial extension?
A sugar-free, low-grit, fruit-mint chewable in moisture-protective blister packaging is the most commercially attractive extension because it creates visible differentiation without requiring a new therapeutic mechanism.
References
-
U.S. National Library of Medicine. (n.d.). DailyMed: Drug labels. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Over-the-counter medicines: Drug facts label. https://www.fda.gov/drugs/understanding-over-counter-medicines/over-counter-medicines-drug-facts-label
-
U.S. Food and Drug Administration. (n.d.). Current good manufacturing practice requirements for drugs. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
